ARCHIVES FOR APRIL 2008
-
Bowe Bell + Howell Selects Benefit Express for Benefits Enrollment and Eligibility Management: Study Shows 16.5% Decrease in Paper and 14.8% Increase in Online Enrollment Saves Companies Time and Money
PR Newswire
ARLINGTON HEIGHTS, Ill., April 30 /PRNewswire/ -- Benefit Express'
comprehensive health and welfare enrollment system has been chosen by
Wheeling-based Bowe Bell + Howell. The three-year contract servicing nearly
2,000 employees, will provide Bowe Bell + Howell with best-of-breed online
benefits enrollment solutions and provide a greater return on their investment
than their previous enterprise resource planning (ERP) system.
-
Aspirin seen cutting risk of type of breast cancer - Reuters
Google
By Will Dunham WASHINGTON (Reuters) - A daily aspirin may give women modest protection against the most common type of breast cancer, US government researchers said on Wednesday.
-
Alzheimer?s Foundation of America Quilt Remembers Moms
PR Newswire
2008 Tour of Heartfelt Collection Begins Mother's Day Weekend
-
Baxa Launches Microsite Featuring the MedBoard(TM) Medication Tracking System
PR Newswire
ENGLEWOOD, Colo., April 30 /PRNewswire/ -- Baxa Corporation announces the
launch of a new microsite featuring its MedBoard Medication Tracking System
(MTS). The site is designed to complement Baxa direct sales efforts and
features an interactive product demonstration and animated workflow.
Customers can use the site's interactive tools to explore MedBoard features
and benefits, as well as download documents covering frequently asked
questions and key product attributes.
-
Cell Therapeutics, Inc. Sells $64.5 million Units Consisting of Preferred Stock, New 2014 Convertible Senior Notes and Warrants to a Single Institutional Investor
PR Newswire
SEATTLE, April 30 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI"
or the "Company") (Nasdaq: CTIC; MTA) today announced that it has entered into
agreements to sell units of securities for approximately $64.5 million,
including new Series E Convertible Preferred Stock (the "Preferred Stock"),
13.5% Convertible Senior Notes due 2014 (the "Notes") and warrants to purchase
shares of common stock, no par value (the "Common Stock") to a single
institutional investor. The aggregate price per unit was $0.3475 cents above
the closing bid of $0.79 per share or $1.14 per unit. Also included is a one-
year right for such investor to purchase up to $67.5 million of such
securities in the future.
-
Report Slams US Food Safety System - Washington Post
Google
By Steven Reinberg WEDNESDAY, April 30 (HealthDay News) -- The current system that guarantees the safety of food in the United States is in a state of crisis, a new report finds.
-
Pharma 2008 to Pharma 2020: the Road Ahead - Telegraph.co.uk
Google
The pharmaceutical industry is currently undergoing a transition. In order to continue to research and develop innovative medicines for patients throughout ...
-
Excruciatingly Embarrassing Moment for The Medical Board of California: Complete Meltdown of the Friday, April 25th Quarterly Meeting: by T. L. Kittle
PR Newswire
LOS ANGELES, April 30 /PRNewswire/ -- On Friday, April 25, the Medical
Board of California had its quarterly meeting in Sacramento, California -- in
the beginning, the meeting started normally, but by the end there were so few
Board members present there wasn't a "quorum", leaving the Board with work
left to do but not enough members to take action.
-
Global food fight - Baltimore Sun
Google
And just yesterday, UN Secretary-General Ban Ki Moon said he plans to establish a task force to tackle that crisis and avert "social unrest on an ...
-
Vicus Therapeutics Records Last Patient Visit of Phase 2, VT-122 Trial for the Treatment of Cachexia in Patients With Advanced Lung Cancer
PR Newswire
MORRISTOWN, N.J., April 30 /PRNewswire/ -- Vicus Therapeutics, LLC, a
biopharmaceutical company focused on oncology supportive care, announced today
the completion of the last patient visit in its study VT1-CAX-001, a Phase 2
trial of VT-122. The compound was tested for the treatment of cachexia in
weight losing subjects with Stage IV, non-small cell lung cancer (NSCLC). The
Phase 2 clinical trial was conducted in India and the final study report is
expected in June 2008.
Health News